
Global Women’s Health Market Report Segmented by Product Type (ACTONEL, FORTEO, Mirena, NuvaRing, Premarin), Application (Female Infertility, Menopause, Endometriosis), Age Group (Adolescents, Adult Women, Elderly Women), End-user & Forecast to 2030
The global women’s health market is expected to grow at a rate of 5% during the forecast period. Rising prevalence of chronic diseases such as breast cancer and osteoporosis, growing demand for contraception and increased initiatives by the government and NGO are some of the key factors driving the market growth. However, side effects associated with the use of contraceptive pills, hormonal therapies and the complex regulatory approval process remain some key barriers for the growth of the women’s health market. To learn more about the research report, download a sample report.
One-half of the world’s population is women, and they account for ~80% of consumer purchasing decisions in the healthcare industry. Women’s health refers to the branch of medicine that focuses on the biological, psychological, and social factors affecting the health and well-being of women throughout their lives. The central focus is on reproductive care, which includes menstruation, contraception, pregnancy, childbirth, and menopause. Additionally, it also addresses the management of other reproductive system disorders such as polycystic ovary syndrome (PCOS), endometriosis, and gynecological cancers like cervical and ovarian cancer.
Beyond reproductive health, women are also at higher risk for several non-reproductive conditions, such as osteoporosis, which is more prevalent in women due to hormonal changes that affect bone density, especially after menopause. Breast cancer remains one of the most prevalent and serious threats to women's health globally. Understanding these unique women’s health concerns is vital to improve early diagnosis, access to treatment or care, and health outcomes for women at every life stage.
To learn more about this report, download the PDF brochure
Growing Burden of Chronic Illness in Women
The increasing incidence of chronic conditions among women, such as cancer and osteoporosis, is the major growth driver of the market. These conditions often require gender-specific measures for prevention, diagnosis, and treatment. The risk factors associated with the occurrence of such diseases are family history, increasing age, early onset of periods or menopause and obesity, among others. For example, in March 2021, the World Health Organization (WHO) initiated the Global Breast Cancer Initiative (GBCI) intending to decrease breast cancer mortality rates by 2.5% annually until 2040, thereby potentially saving 2.5 million lives. With the growing focus on prevention and awareness programs, more women are being diagnosed with critical health conditions, driving the demand for products and services designed for women’s health care. For instance,
- In February 2024, Hologic, Inc. launched the first digital cytology system using advanced volumetric imaging for the detection of precancerous and cervical cancer cells in the US
Rising Demand for Contraceptives to Drive the Women’s Health Market
The growing demand for contraceptives is a significant driver for the women's health market. As awareness about family planning and reproductive health increases, more women are opting for various contraceptive methods to control their fertility and prevent unintended pregnancies. This demand is fueled by educational initiatives, improved access to healthcare services, and a shift towards proactive health management. Contraceptives, including oral pills, intrauterine devices (IUDs), implants, and injectables, offer women the ability to plan their families and careers, contributing to better overall health and economic stability. Additionally, the rise of new and improved contraceptive technologies, such as long-acting reversible contraceptives (LARCs), provides more options that cater to different preferences and needs. Government and non-governmental organizations' efforts to promote contraceptive use and improve accessibility, particularly in developing regions, further bolster this market
To learn more about this report, download the PDF brochure
Technological innovations in women’s healthcare
Advancements in diagnostic technologies have enabled early and precise detection of diseases such as breast cancer, osteoporosis, and reproductive disorders. Digital health tools such as telehealth platforms, mobile apps and wearable devices are now assisting women to take care of their health in a more personalized way. These tools enable continuous health tracking, symptom monitoring, medication reminders, and virtual consultations, increasing accessibility to care, especially in remote and underserved areas. Further, the integration of AI & M/L in the diagnosis and treatment of various diseases has created new opportunities and demands in the market.
- In January 2025, GE HealthCare introduced its enhanced Voluson Expert Series (models 22, 20, 18), which received FDA‑clearance, featuring AI-powered imaging, advanced automation (like SonoLyst and Graphicflow), and ergonomic design to boost early detection and exam efficiency in women’s health ultrasound
- In March 2024, Sirio Pharma unveiled a personalized 25‑formulation women’s health platform at Vitafoods Europe, featuring gummies and softgels tailored to life stages from puberty through menopause, addressing PMS, fertility, prenatal/postnatal care, UTI protection, gut health, weight management, sleep, and menopausal wellbeing
- In February 2023, Samsung HERA W10 Elite ultrasound system was launched, which was designed for Obstetrics and Gynecology, offering advanced imaging capabilities and AI-powered tools
Emerging Opportunities in Women’s Health Market
A new era of innovation is unfolding in women’s health, which is driven by groundbreaking scientific and technological advancements, thereby offering transformative opportunities to address long-standing gaps in diagnosis, treatment, and care. Conditions such as preeclampsia, endometriosis, and hormone-related disorders—are now being explored with greater precision and purpose. Emerging fields like genomics, tissue engineering, artificial intelligence, and cell and gene therapy are unlocking novel ways to develop targeted solutions for female-specific health challenges. For example, researchers are studying transcriptomics (the study of RNA molecules in a cell) for treating elusive conditions such as preeclampsia or preterm birth. On the other hand, tissue engineering is being used to create uterine organoids to push the knowledge frontier on endometriosis. Genomics is another research area that can help researchers in realizing the potential of personalized medicine. There has been extraordinary growth in terms of technology from predictive AI solutions to modelling unique DNA profiles, which uses machine learning algorithms to analyse user data to provide unique, actionable insights and treatment plans related to symptom progression. A favourable environment for research activities is expected to further drive growth opportunities in this market.
“Women’s health is not a niche market; it includes much more than just maternal or reproductive care. Indeed, women’s healthcare presents enormous opportunities for value creation and for improving the lives and livelihoods of women, with positive effects that redound across society"
- Executive Vice President, Global Operations and Supply Chain, Women’s Health Company, United States
Product Type Segment Analysis
The women’s health market comprises two products like: ACTONEL, YAZ (Yasmin, Yasminelle), FORTEO, Mirena, NuvaRing, ORTHO TRI-CY LO, Premarin, Prolia, Reclast/Aclasta, XGEVA, Zometa, Others. The Prolia segment is likely to lead the market and is projected to grow at the fastest rate over the forecast period. Prolia, whose generic name is denosumab, is a medication used in women's health for treating and preventing osteoporosis in postmenopausal women. It is widely used for the treatment of osteoporosis in postmenopausal women at high risk of fractures. Prolia has established a significant market presence due to its effectiveness in reducing the incidence of fractures and its biannual dosing regimen, which improves patient compliance compared to other osteoporosis treatments.
The Minastrin 24 Fe segment is expected to grow at a lucrative CAGR over the forecast period due to its user-friendly dosing schedule and minimal side effects. It combines low-dose estrogen with progestin and iron, which helps manage both birth control and iron deficiency, appealing to women seeking dual benefits. The 24-day active pill regimen, with fewer placebo days, is preferred for its convenience and reduced occurrence of withdrawal bleeding. Additionally, increasing awareness of hormonal contraception's benefits and growing demand for effective, well-tolerated contraceptive options contribute to Minastrin 24 Fe's expanding market presence.
Application Type Segment Analysis
The women’s health market can be analyzed based on application types, such as Female Infertility, Contraceptives, Postmenopausal osteoporosis, Endometriosis, Menopause, and Others. The contraceptives represent the largest segment. The widespread use of contraceptives for both pregnancy prevention and management of menstrual-related issues drives this large market segment. Contraceptives benefit from extensive awareness, strong demand, and ongoing innovation, which maintains their dominant position. The fastest-growing segment is postmenopausal osteoporosis. The incidence of osteoporosis among postmenopausal women is increasing continuously. This growth is driven by an aging demographic, rising awareness of bone health, and advancements in treatment options. Additionally, increased focus on preventive care and proactive management of bone density is accelerating growth in this area. The combination of a growing patient population and a heightened emphasis on osteoporosis prevention and treatment supports its position as the fastest-growing segment in the women’s health market.
Growth Strategies Adopted by Players to Establish Their Foothold in the Market
Players operating in this market are adopting different growth strategies such as new product launches and approvals to garner market share. For instance,
- In May 2024, The FDA approved Sandoz’s Jubbonti and Wyost as interchangeable biosimilars to Prolia and Xgeva, respectively, for treating certain types of osteoporosis and preventing bone events in cancer. These approvals enhance treatment accessibility and demonstrate the biosimilars' similar safety and efficacy to their reference products
- In January 2024, Bayer Healthcare’s Mirena, a 52mg Levonorgestrel IUD, received FDA approval for contraceptive to extend of this device, for contraception only, to eight years. The approval is particularly beneficial for younger perimenopausal women needing contraception, while the license for treating heavy menstrual bleeding and endometrial protection remains unchanged
- In November 2023, Teva Pharmaceuticals received USFDA of a generic version of Forteo (teriparatide injection) for osteoporosis treatment. This approval enhances patient access to osteoporosis treatment and supports Teva’s goal of maintaining its position as a leading generic pharmaceutical company
The women’s health market is expected to gain further momentum in the coming years due to impending patent cliff, rising R&D investments, new product launches, and aggressive organic and inorganic growth strategies followed by the players.
Competitive Landscape Analysis
The global women’s health market is marked by the presence of established and emerging market players such as Bayer AG, Amgen, AbbVie, Pfizer, Ferring Pharmaceutical, Novartis, Organon & Co., Apothecus Pharmaceutical Corp, Theramex, and Blairex Laboratories. Some of the key strategies adopted by market players include new product development, strategic partnerships and collaborations, and geographic expansion.
Report Scope
Report Metric | Details |
Base Year Considered | 2024 |
Historical Data | 2023 - 2024 |
Forecast Period | 2025 – 2030 |
Growth Rate | 5% |
Market Drivers |
|
Attractive Opportunities |
|
Segment Scope | Product Type, Application, Age Group and End-user |
Regional Scope |
|
Key Companies Mapped | Bayer AG, Amgen, AbbVie, Pfizer, Ferring Pharmaceutical, Novartis, Organon & Co., Apothecus Pharmaceutical Corp, Theramex, and Blairex Laboratories, among others |
Report Highlights | Market Size & Forecast, Growth Drivers & Restraints, Trends, Competitive Analysis |
Global Women’s Health Market Segmentation
This report by Medi-Tech Insights provides the size of the global women’s health market at the regional- and country-level from 2023 to 2030. The report further segments the market based on product type, application, age group and end-user.
Market Size & Forecast (2023-2030), By Product Type, USD Million
- ACTONEL
- YAZ, Yasmin, Yasminelle
- FORTEO
- Mirena
- NuvaRing
- ORTHO TRI-CY LO
- Premarin
- Prolia
- Reclast/Aclasta
- XGEVA
- Zometa
- Others
Market Size & Forecast (2023-2030), By Application, USD Million
- Female Infertility
- Contraceptives
- Postmenopausal Osteoporosis
- Menopause
- Endometriosis
- Others
Market Size & Forecast (2023-2030), By Age Group, USD Million
- Adolescents
- Adult Women
- Elderly Women
Market Size & Forecast (2023-2030), By End-user, USD Million
- Hospitals
- Clinics
- Homecare settings
- Others
Market Size & Forecast (2023-2030), By Region, USD Million
- North America
- US
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Rest of Asia Pacific
- Latin America
- Middle East & Africa
Key Strategic Questions Addressed
- What is the market size & forecast of the women’s health market?
- What are historical, present, and forecasted market shares and growth rates of various segments and sub-segments of the women’s health market?
- What are the key trends defining the market?
- What are the major factors impacting the market?
- What are the opportunities prevailing in the market?
- Which region has the highest share in the global market? Which region is expected to witness the highest growth rate in the next 5 years?
- Who are the major players operating in the market?
- What are the key strategies adopted by players?
- Introduction
- Introduction
- Market Scope
- Market Definition
- Segments Covered
- Regional Segmentation
- Research Timeframe
- Currency Considered
- Study Limitations
- Stakeholders
- List of Abbreviations
- Key Conferences and Events (2025-2026)
- Research Methodology
- Secondary Research
- Primary Research
- Market Estimation
- Bottom-Up Approach
- Top-Down Approach
- Market Forecasting
- Executive Summary
- Women’s Health Market Snapshot (2025-2030)
- Segment Overview
- Regional Snapshot
- Competitive Insights
- Market Overview
- Market Dynamics
- Drivers
- Rising prevalence of chronic conditions among women
- Growing demand for contraceptives
- Rising awareness and focus on preventive care for women’s health issues
- Increasing government and NGO support for maternal health
- Technological advancement in diagnostics and telemedicine for women's health
- Restraints
- High cost of advanced reproductive and diagnostic procedures
- Side effects associated with the use of contraceptive pills and hormonal therapies
- Complex regulatory approval process
- Opportunities
- Growth in femtech and personalized mobile health solutions
- Increased focus on women's mental health
- Rising demand for non-invasive diagnostic and therapeutic devices
- Untapped rural and emerging markets for women’s wellness products
- Key Market Trends
- Integration of AI and digital tools for menstrual and fertility tracking
- Shift toward natural and plant-based hormone replacement therapies
- Unmet Market Needs
- Industry Speaks
- Global Women’s Health Market Size & Forecast (2023-2030), By Product Type, USD Million
- Introduction
- ACTONEL
- YAZ, Yasmin, Yasminelle
- FORTEO
- Mirena
- NuvaRing
- ORTHO TRI-CY LO
- Premarin
- Prolia
- Reclast/Aclasta
- XGEVA
- Zometa
- Others
- Global Women’s Health Market Size & Forecast (2023-2030), By Application, USD Million
- Introduction
- Female Infertility
- Contraceptives
- Post Menopausal Osteoporosis
- Menopause
- Endometriosis
- Others
- Global Women’s Health Market Size & Forecast (2023-2030), By Age Group, USD Million
- Introduction
- Adolescents
- Adult Women
- Elderly Women
- Global Women’s Health Market Size & Forecast (2023-2030), By End-user, USD Million
- Introduction
- Hospitals
- Clinical Labs
- Home Care Settings
- Others
- Global Women’s Health Market Size & Forecast (2023-2030), By Region, USD Million
- Introduction
- North America Women’s Health Market Size & Forecast (2023-2030), By Country, USD Million
- US
- Market Size & Forecast, By Product Type (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By Age Group (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- Canada
- Market Size & Forecast, By Product Type (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By Age Group (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- US
- Europe Women’s Health Market Size & Forecast (2023-2030), By Country, USD Million
- UK
- Market Size & Forecast, By Product Type (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By Age Group (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- Germany
- Market Size & Forecast, By Product Type (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By Age Group (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- France
- Market Size & Forecast, By Product Type (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By Age Group (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- Italy
- Market Size & Forecast, By Product Type (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By Age Group (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- Spain
- Market Size & Forecast, By Product Type (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By Age Group (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- Rest of Europe
- Market Size & Forecast, By Product Type (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By Age Group (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- UK
- Asia Pacific (APAC) Women’s Health Market Size & Forecast (2023-2030), By Country, USD Million
- China
- Market Size & Forecast, By Product Type (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By Age Group (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- Japan
- Market Size & Forecast, By Product Type (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By Age Group (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- India
- Market Size & Forecast, By Product Type (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By Age Group (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- Rest of Asia Pacific
- Market Size & Forecast, By Product Type (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By Age Group (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- China
- Latin America (LATAM) Women’s Health Market Size & Forecast (2023-2030), USD Million
- Market Size & Forecast, By Product Type (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By Age Group (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- Middle East & Africa (MEA) Women’s Health Market Size & Forecast (2023-2030), USD Million
- Market Size & Forecast, By Product Type (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By Age Group (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- Competitive Landscape
- Key Players and their Competitive Positioning
- Key Player Comparison
- Segment-wise Player Mapping
- Market Share Analysis (2024)
- Company Categorization Matrix
- Dominants/Leaders
- New Entrants
- Emerging Players
- Innovative Players
- Key Strategies Assessment, By Player (2022-2025)
- New Product Launches
- Partnerships, Agreements, & Collaborations
- Mergers & Acquisitions
- Geographic Expansion
- Key Players and their Competitive Positioning
- Company Profiles*
(Business Overview, Financial Performance**, Products Offered, Recent Developments)
- Bayer AG
- Amgen
- Abbvie
- Pfizer
- Ferring Pharmaceutical
- Novartis
- Organon and Co
- Apothecus Pharmaceutical Corp
- Theramex
- Blairex Laboratories
- Other Prominent Players
Note: *Indicative list
**For listed companies
The study has been compiled based on extensive primary and secondary research.
Secondary Research (Indicative List)
Primary Research
To validate research findings (market size & forecasts, market segmentation, market dynamics, competitive landscape, key industry trends, etc.), extensive primary interviews were conducted with both supply and demand-side stakeholders.
Supply Side Stakeholders:
- Senior Management Level: CEOs, Presidents, Vice-Presidents, Directors, Chief Technology Officers, Chief Commercial Officers
- Mid-Management Level: Product Managers, Sales Managers, Brand Managers, R&D Managers, Business Development Managers, Consultants
Demand Side Stakeholders:
- Stakeholders from Hospitals, Clinical Laboratories, and Others
Breakdown of Primary Interviews
Market Size Estimation
Both ‘Top-Down & Bottom-Up Approaches’ were used to derive market size estimates and forecasts
Data Triangulation
Research findings derived through secondary sources & internal analysis was validated with Primary Interviews, Internal Knowledge Repository and Company’s Sales Data